Operating companies brought 41 of the 56 suits, or 73.2%. Non practicing entities brought 15. A device company facing a complaint is most likely facing a competitor.
Those competitors assert patents they prosecuted rather than bought. Only 23.1% of operating company assertions here were acquired, against 78.0% on the non practicing side and 49.9% across all industries. The portfolios are built in house alongside the products.
61.5% of the patents competitors assert are continuations, and the industry as a whole runs at 59.3% against a 44.5% norm. A live continuation chain means claims can still be drafted against a device already cleared and shipping, which is a different exposure from a fixed set of issued claims.
What this cannot tell you. The dataset records filings, parties and asserted patents, not results, so settlement rates, IPR institution rates and dismissal figures all fall outside it. Nothing here describes what a matter costs to defend or how it ends.
Using this on a live matter
Three questions answerable from public records in the first hour after a complaint or demand letter arrives, and what each answer usually means in this industry.
Is the continuation chain still open?
61.5% of the patents competitors assert here are continuations. An open chain lets the asserter draft new claims against the accused device while the case runs. Pulling the continuity data on the asserted family is worth doing before the claim charts arrive.
Did the asserter file the patent or buy it?
Competitors here assert patents they prosecuted 76.9% of the time. Non practicing assertions were acquired 78.0% of the time. The two populations sit at opposite ends of the same measure, so assignment history sorts this docket more cleanly than almost any other attribute.
Is the accused product a device, or a device with a drug in it?
A61K, the class covering preparations for medical purposes, carries 23 asserted patents here and every one came from an operating company. A combination product draws formulation claims alongside the mechanical ones, and those follow the pharmaceutical pattern rather than the device pattern.
Who is doing the asserting
of cases came from companies that sell a competing product.
Pharmaceuticals recorded no non practicing filings at all across 67 cases. Consumer goods runs at 57.1% operating company. At the other end, financial services sits at 9.5% and telecommunications at 12.0%. Every case in this window carried a classified asserter.
Only 13 distinct non practicing entities filed here, and the largest brought two cases. Non practicing volume has stayed between zero and five a quarter for two years with no trend.
No case in this window was left unclassified, so 73.2% is both the classified share and the share of all filings.
What a defensive portfolio reaches
A portfolio held for deterrence works by giving the other side something to lose if it is sued back. The mechanism needs an opponent whose own products can infringe.
suits came from a company with a cleared, marketed device, and a countersuit reaches every one of them.
A competitor asserting a device patent has products on the market, a regulatory footprint and revenue that a counterclaim can reach.
The portfolios on both sides are built the same way. Competitors assert patents they filed 76.9% of the time, from families with a median of 17 members. A counterclaim is met by a party holding an equivalent instrument, which shapes these disputes toward cross licensing rather than toward a one sided damages claim.
Three of the 53 companies sued appear elsewhere in this data as an asserting party, and the remaining 26.8% of matters arrive from parties a portfolio cannot reach.
Who is getting sued
No company with market capitalization above $200 billion was sued in this industry during the window. 39 companies with no public listing absorbed 41 cases between them, or 73% of the industry total.
Cases by defendant size
56 cases across 53 distinct medical device defendants.
Fifty three companies absorbed 56 cases, an average of 1.06 each, so repeat exposure is rare. The largest listed defendants sit in the $10 billion to $200 billion band and account for 11 cases. Volume rests with private device makers, many of them single product companies.
What they assert on
Most asserted patents carry a primary CPC subclass. All six charted classes sit in A61, the medical and veterinary section, and together they hold 69% of everything asserted in this industry.
Asserted patents by technology area
138 patents with a primary CPC classification, split by asserting party type.
A61B24.6% of asserted patentsA61K16.7%A61M10.1%A61F9.4%A61N4.3%A61C3.6%Two kinds of asserted patent
Patents asserted by non practicing entities differ from those asserted by operating companies on attributes visible in the public record. The non practicing column rests on 44 patent records across 15 cases and is reported with that limit attached.
| Attribute | Asserted by NPEs | Asserted by op. co. | Spread |
|---|---|---|---|
| Share acquired rather than original | 78.0% | 23.1% | −54.9 pts |
| Median years from grant to suit | 10.2 | 5.5 | 1.9× |
| Median years from priority to suit | 18.8 | 12.1 | 1.6× |
| Median simple family size | 6 | 17 | op. co. 2.8× |
| Share that are continuations | 53.7% | 61.5% | +7.8 pts |
Two years of filings
Cases filed per quarter against medical device defendants
By asserting party type. 2026 Q3 is partial and the data ends 10 August 2026.
Operating company filings moved between 4 and 13 a quarter across the eight complete quarters with no direction, and non practicing filings between 0 and 5. Software, semiconductors and mechanical all doubled or more over the same period. Medical device litigation volume in this window is stable, and a forecast built on the last eight quarters would have been close to right in each of them.
Recent assertions by operating companies
Competitor suits are the bulk of this docket. The four below are the most recent operating company suits classified as disputes between direct competitors.
- Competitive
OsteoMed LLC v. Wright Medical Technology, Inc.
4 patents · orthopedic fixation
- Competitive
Parting Stone, Inc. v. Biolife, LLC
1 patent · post mortem processing · neither party is public
- Competitive
Serendia, LLC v. BTL Industries, Inc.
1 patent · aesthetic and dermatological devices
- Competitive
TSK Laboratory Europe B.V. v. Kabushikigaisha Tasuku
1 patent · needle and injection technology · two non United States parties
All four landed within four weeks of each other, and three rest on a single patent. Competitor litigation here is narrow, aimed at one mechanism in one product line. Competitive relationship labels come from model classification in the source data rather than from court findings.
Portfolio attributes across all assertions
- Acquired patents
- All industries: 49.9%
- Median grant → suit
- All industries: 6.3 yrs
- Median priority → suit
- All industries: 13.1 yrs
- Continuations
- All industries: 44.5%
- Median simple family
- All industries median 8 · average here 15.7
- Avg independent claims
- 20.5 total claims average
Medical device assertions sit near the cross industry norm on both age measures and well away from it on structure. Continuation share is fifteen points above average and acquisition is eleven points below. Independent claim counts average 2.5. The profile describes narrow claims inside deep, live families, prosecuted by the parties asserting them.
Most active asserters in window
Entities that do not practice
- Genesis Growth Tech LLC
- e-Beacon LLC
- Artificial Intelligence Imaging Association, Inc.
- Faunus IP Holdings LLC
The second entry combines one case filed as e-Beacon LLC with one filed as E-BEACON LLC. Thirteen distinct entities brought the 15 non practicing cases.
Operating companies
- CAO Group, Inc.
- Zehnder Consulting
- 3B Medical Manufacturing, LLC
- AngioDynamics, Inc.
- Apnea Sciences Corporation
Neither side has a repeat filer of any size. The largest asserter in this industry brought two cases, against 26 for the largest in financial services. Forty one operating company suits came from a long list of companies each appearing once or twice, which is what a docket of ordinary competitor disputes looks like.